NEW HORIZON FOR TREATMENT IN...
Emerging therapies for coeliac disease: beyond the gluten-free diet
Maria Boccia, Valentina Discepolo
European Laboratory for the Investigation of Food-Induced Diseases (ELFID), University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy.
Coeliac disease is a chronic immune-mediated enteropathy triggered by dietary gluten in genetically susceptible individuals. A strict gluten-free diet remains the only established effective and safe treatment. However, a life-long avoidance of gluten is difficult to achieve and maintain. Advances in disease pathogenesis have identified therapeutic targets at the luminal, epithelial and immune levels. Gluten-degrading enzymes are intended to reduce exposure to immunogenic peptides, whereas intestinal barrier modulators and tissue transglutaminase 2 inhibitors act before or during antigen presentation. Other agents target inflammatory pathways or aim to induce antigen-specific immune tolerance. Oral inhibition of tissue transglutaminase 2 has attenuated gluten-induced mucosal injury in a phase 2 trial, while engineered glutenases and tolerogenic platforms have progressed through clinical development. Nevertheless, no pharmacological treatment has been approved as an alternative to the gluten-free diet, and paediatric efficacy and safety data remain limited. In the future, these interventions are most likely to be evaluated as adjuncts to dietary treatment, particularly for protection against inadvertent gluten exposure or for persistent disease activity. Demonstration of sustained mucosal protection, clinically relevant efficacy and long-term safety will be essential before their integration into paediatric practice.